Centre hospitalier universitaire de Sherbrooke, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, QC.
Curr Oncol. 2019 Feb;26(1):e64-e69. doi: 10.3747/co.25.4244. Epub 2019 Feb 1.
Stereotactic radiosurgery (srs) for patients with 5 or more brain metastases (bmets) is a matter of debate. We report our results with that approach and the factors influencing outcome.
In the 103 patients who underwent srs for the treatment of 5 or more bmets, primary histology was non-small-cell lung cancer (57% of patients). All patients were grouped by Karnofsky performance status and recursive partitioning analysis (rpa) classification. In our cohort, 72% of patients had uncontrolled extracranial disease, and 28% had stable or responding systemic disease. Previous irradiation for 1-4 bmets had been given to 56 patients (54%). The mean number of treated bmets was 7 (range: 5-19), and the median cumulative bmets volume was 2 cm (range: 0.06-28 cm).
Multivariate analyses showed that stable extracranial disease ( < 0.001) and rpa ( = 0.022) were independent prognostic factors for overall survival (os). Moreover, a cumulative treated bmets volume of less than 6 cm (adjusted hazard ratio: 2.54; = 0.006; 95% confidence interval: 1.30 to 4.99) was associated with better os. The total number of bmets had no effect on survival ( = 0.206). No variable was found to be predictive of local control. The rpa was significant ( = 0.027) in terms of distant recurrence.
Our study suggests that srs is a reasonable option for the management of patients with 5 or more bmets, especially with a cumulative treatment volume of less than 6 cm.
对于 5 个或以上脑转移瘤(BMETs)的患者,立体定向放射外科(SRS)的应用存在争议。我们报告了采用该方法治疗 5 个或以上 BMETs 的结果以及影响疗效的因素。
103 例接受 SRS 治疗 5 个或以上 BMETs 的患者中,原发性组织学为非小细胞肺癌(57%的患者)。所有患者按 Karnofsky 表现状态和递归分区分析(RPA)分类分组。在我们的队列中,72%的患者有不可控制的颅外疾病,28%的患者有稳定或应答的全身疾病。56 例(54%)患者之前接受过 1-4 个 BMETs 的放疗。治疗的 BMETs 数量中位数为 7(范围:5-19),累积 BMETs 体积中位数为 2cm(范围:0.06-28cm)。
多变量分析表明,稳定的颅外疾病(<0.001)和 RPA(=0.022)是总生存(OS)的独立预后因素。此外,累积治疗 BMETs 体积小于 6cm(调整后的危险比:2.54;=0.006;95%置信区间:1.30 至 4.99)与更好的 OS 相关。BMETs 的总数对生存没有影响(=0.206)。没有变量可以预测局部控制。RPA 对远处复发具有显著意义(=0.027)。
我们的研究表明,SRS 是治疗 5 个或以上 BMETs 的合理选择,尤其是累积治疗体积小于 6cm 的患者。